Generic Name and Formulations:
Luliconazole 1%; cream.
Valeant Pharmaceuticals, Inc
Indications for LUZU:
Interdigital tinea pedis, t. cruris, and t. corporis caused by Trichophyton rubrum and Epidermophyton floccosum.
Adults and Children:
Apply to affected area and approximately 1 inch of the immediate surrounding area(s) once daily. T. corporis (≥2yrs): treat for 1 week. T. pedis (≥12yrs): treat for 2 weeks. T. cruris (≥12yrs): treat for 1 week.
Not for ophthalmic, oral, or intravaginal use. Pregnancy. Nursing mothers.
May inhibit CYP2C19 activity.
Application site reactions.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|